Associate Professor of Pathology
Office Phone: 202-677-6600
- MD, YAZD University of Medical Sciences, 1992
Katayoon Rezaei, M.D. is an Associate Professor in the Department of Pathology at the George Washington (GW) University and serves as the Chief of Cytopathology Services. She completed her residency in Anatomic and Clinical Pathology at GW, followed by two years of Fellowships in Surgical Pathology and Cytopathology. Dr. Rezaei is Board certified in Anatomic and Clinical Pathology with subspecialty Board certification in Cytopathology. She joined the Faculty of the GW Department of Pathology in 2005, where she provides clinical diagnostic services, and serves as core faculty for the Pathology Residency and Fellowship training programs. In the greater professional community of Pathology, Dr. Rezaei is an advocate for best practices in pathology and laboratory medicine and is actively involved in representing interests of pathologists on Capitol Hill. She is currently serving as the Delegation Chair of the District of Columbia for the College of American Pathologists and a member of the Federal and State Affairs Committee.
Dr. Rezaei’s clinical practice focuses mainly on Urologic pathology and Cytopathology. In addition to the diagnostic services, she is an active member of multidisciplinary urologic oncology team. As the Chief of Cytopathology, Dr. Rezaei provides diagnostic services in GYN and Non-GYN cytology, with emphasis on cytology based molecular assays in cervical cancer screening and bladder cancer. She also accepts patients for performing Fine Needle Aspiration of thyroid, salivary gland, lymph nodes, and other superficial lesions with an additional certification from the College of American Pathologists in performing ultrasound-guided FNA.
Dr. Rezaei’s research focuses on biomarker discovery and prognostics of cancers and precancers. Within the institution, she has worked with the researchers at the GW Genomic Medicine, on the biomarker identification and validation for the early diagnosis and treatment of breast cancer. She has also collaborated in multi-institutional studies relating to bladder cancer biomarkers and genital squamous intraepithelial lesions.
View publications by this faculty member.
Stier EA, Lensing SY, Darragh TM, Deshmukh AA, Einstein MH, Palefsky JM, Jay N, Berry-Lawhorn JM, Wilkin T, Wiley DJ, Barroso LF, Cranston RD, Levine R, Guiot HM, French AL, Citron D, Rezaei MK, Goldstone SE, Chiao E. Prevalence of and Risk Factors for Anal High-grade Squamous Intraepithelial Lesions in Women Living with Human Immunodeficiency Virus. Clin Infect Dis. 2020 Apr 10;70(8): 1701-1707. PMID: 31292602
Rodriguez Pena MDC, Chaux A, Eich ML, Tregnago AC, Taheri D, Borhan W, Sharma R, Rezaei MK, Netto GJ. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Arch. 2019 Sep;475(3):349-356. PMID:31300876
Tan X, Li Z, Ren S, Rezaei K, Pan Q, Goldstein AT, Macri CJ, Cao D, Brem RF, Fu SW. Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer. Breast Cancer Res. 2019 Aug 7;21(1):89. PMID: 31391072
Eich ML, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, Baras AS, Hahn NM, Drake C, Sharma R, Bivalacqua TJ, Rezaei K, Netto GJ. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder. Hum Pathol. 2019 Jul;89:24-32. PMID: 31026471
Chakravarthi BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, Hodigere Balasubramanya SA, Jabboure FJ, Matoso A, Bivalacqua TJ, Rezaei K, Chaux A, Grizzle WE, Sonpavde G, Gordetsky J, Netto GJ, Varambally S. A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. Neoplasia. 2018 Sep;20(9):894-904. PMID: 30121007
Frost AS, Sherman JH, Rezaei K, Aron A, Lopez-Acevedo M. Choriocarcinoma with brain, lung and vaginal metastases successfully treated without brain radiation or intrathecal chemotherapy: A case report. Gynecol Oncol Rep. 2017 Mar 25;20:97-99. PMID: 28393093
Pezhouh MK, Rezaei MK, Shabihkhani M, Ghosh A, Belchis D, Montgomery EA, Voltaggio L. Clinicopathologic study of calcifying fibrous tumor of the gastrointestinal tract: a case series. Hum Pathol. 2017 Apr;62:199-205. PMID: 28153506
Tan X, Fu Y, Chen L, Lee W, Lai Y, Rezaei K, Tabbara S, Latham P, Teal CB, Man YG, Siegel RS, Brem RF, Fu SW. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer. Oncotarget. 2016 Jan 5;7(1):293-307. doi: 10.18632/oncotarget.6344. PMID: 26588055
Shen F, Mo MH, Chen L, An S, Tan X, Fu Y, Rezaei K, Wang Z, Zhang L, Fu SW. MicroRNA-21 Down-regulates Rb1 by Targeting PDCD4 in Retinoblastoma. J Cancer. 2014 Nov 21;5(9):804-12. PMID: 25520758
Tian W, Guner G, Miyamoto H, Cimino-Mathews A, Gonzalez-Roibon N, Argani P, Li X, Sharma R, Subhawong AP, Rezaei K, Bivalacqua TJ, Epstein JI, Bishop JA, Netto GJ. Utility of uroplakin II expression as a marker of urothelial carcinoma. Hum Pathol. 2014 Oct 2. pii: S0046-8177(14)00373-6. PMID: 25449628
Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, Teal CB, Man YG, Brem RF, Fu SW. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple negative breast cancer. Breast Cancer Res. 2014 Sep 17;16(5):435. PMID: 25228385
Industry Relationships and Collaborations
This faculty member (or a member of their immediate family) has reported a financial interest with the health care related companies listed below. These relations have been reported to the University and, when appropriate, management plans are in place to address potential conflicts.